Thromboxane B2

Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation. Thromboxane B2 is a biological inactive product and circulating catabolite of thromboxane A2. Thromboxane B2 levels in peripheral venous blood and coronary sinus blood can be used as a diagnostic marker for angina. Thromboxane B2 level in serum is also associated with inhibition of COX-1 activity inhibition in platelets. Thromboxane B2 is a major product of prostaglandin endoperoxide metabolism. Thromboxane B2 produces dose-related decreases in airflow rate, tidal volume and dynamic lung compliance, whilst simultaneously increasing pulmonary airway resistance in dog model. Thromboxane B2 appears to be a naturally occurring bronchoactive metabolite in the bioconversion of arachidonic acid^[1][2][3]. In Vitro:Thromboxane B2 (1 μM-1 mM) has an EC_15mm value of 8.7 M in isolated guinea pig tracheal contraction induction^[3]. In Vivo:Thromboxane B2 (30 μg/kg, i.v., single dose) decreases the tidal volume, expiratory airflow rate and dynamic lung compliance in canine model^[3].